Press releases
- Press releases
- Browse
Press releases
Strong progress made in advancing our key drug development programs More
MONTREAL, PQ - ConjuChem Inc. (TSX:CJC), today announced the initiation of healthy volunteer dosing as part of a Phase I clinical trial for DAC:GLP-1TM (CJC-1131), a compound under development for the treatment of Type 2 diabetes. More
Ferring will collaborate with Ortho-McNeil to research and develop Ferring's inhibitors inhibitors of dipeptidyl peptidase IV (DP IV) for use in the treatment of diabetes and obesity. More
- SignalGene and Genome Quebec Establish New Biotherapeutics Company - More
Related Reports
Market Research Reports provided by reports.iptechex.com
Jun 2010 - 160 pages - $3,995
Jan 2011 - 99 pages - $3,835
Aug 2010 - 80 pages - $1,215
Nov 2007 - 45 pages - $495
Dec 2009 - 24 pages - $495
Jan 2008 - 48 pages - $495
Dec 2009 - 23 pages - $495
Dec 2009 - 24 pages - $495
Dec 2009 - 24 pages - $495
Dec 2009 - 24 pages - $495
Your selection
Browse By
- Industry sector
- Bioinformatics
- Combinatorial biology
- Combinatorial chemistry
- Drug research platforms
- Genomics
- High throughput screening
- Proteomics
- Therapeutic target
- Anorexia
- Anti-oxidant
- Appetite
- Bulimia nervosa
- Cachexia
- Cirrhosis
- Diabetes type I
- Diabetes type II
- Diabetic complications
- Fabry's disease
- Gallbladder disorder (other)
- Gallstones
- Gaucher's disease
- Hepatic protectors
- Hepatic protectors
- Hypercholesterolemia
- Hyperparathyroidism
- Hypertriglyceridemia
- Liver cancer
- Liver disorders (other)
- Metabolic disorder (other)
- Mineral supplement
- Obesity
- Weight loss
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us